{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:44:04Z","timestamp":1781196244511,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":3106,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1097\/jto.0b013e318060d329","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T11:09:19Z","timestamp":1209899359000},"page":"537-543","source":"Crossref","is-referenced-by-count":32,"title":["Independent Review of Interstitial Lung Disease Associated with Death in TRIBUTE (Paclitaxel and Carboplatin with or without Concurrent Erlotinib) in Advanced Non-small Cell Lung Cancer"],"prefix":"10.1016","volume":"2","author":[{"given":"Ken Y.","family":"Yoneda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David K.","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel A.","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gandara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e318060d329_bib1","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"10.1097\/JTO.0b013e318060d329_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signaling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1097\/JTO.0b013e318060d329_bib3","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(02)00966-2","article-title":"Ligand-induced, receptor-mediated dimerization and activation of EGF receptor","volume":"110","author":"Schlessinger","year":"2002","journal-title":"Cell"},{"key":"10.1097\/JTO.0b013e318060d329_bib4","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)","volume":"21","author":"Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib5","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1001\/jama.290.16.2149","article-title":"Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial","volume":"290","author":"Kris","year":"2003","journal-title":"JAMA"},{"key":"10.1097\/JTO.0b013e318060d329_bib6","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non\u2013small-cell lung cancer","volume":"22","author":"Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e318060d329_bib8","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/S0140-6736(05)67625-8","article-title":"Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)","volume":"366","author":"Thatcher","year":"2005","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e318060d329_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib10","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib11","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2004.22.14_suppl.7010","article-title":"Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell cancer (NSCLC)","author":"Gatzemeier","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.cad.0000127666.12215.7b","article-title":"Acute lung injury as an adverse event of gefitinib","volume":"15","author":"Inomata","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1097\/JTO.0b013e318060d329_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1634\/theoncologist.8-4-303","article-title":"FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets","volume":"8","author":"Cohen","year":"2003","journal-title":"Oncologist"},{"key":"10.1097\/JTO.0b013e318060d329_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"Oncologist"},{"issue":"Suppl","key":"10.1097\/JTO.0b013e318060d329_bib16","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","article-title":"Interstitial lung disease associated with drug therapy","volume":"91","author":"Camus","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e318060d329_bib17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.lungcan.2006.02.002","article-title":"Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group","volume":"52","author":"Endo","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e318060d329_bib18","first-page":"619s","article-title":"TRIBUTE - A phase III trial of erlotinib HCI (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)","volume":"23","author":"Herbst","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib19","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1200\/JCO.2005.05.030","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?","volume":"23","author":"Gandara","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib20","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2165\/00002018-200427140-00002","article-title":"Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer","volume":"27","author":"Forsythe","year":"2004","journal-title":"Drug Saf"},{"key":"10.1097\/JTO.0b013e318060d329_bib21","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib22","first-page":"628","article-title":"Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchoalveolar carcinoma (BAC) (Abstract 7062)","volume":"23","author":"Kris","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib23","doi-asserted-by":"crossref","DOI":"10.1090\/S0002-9939-03-07068-0","article-title":"Preliminary results from a phase II study of the EGFR tyrosine kinase inhibitor erlotinib in patients >70 years of age with previously untreated advanced non-small cell lung carcinoma","author":"Johnson","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1097\/JTO.0b013e318060d329_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1053\/crad.2001.0792","article-title":"Drug-induced lung disease: high-resolution CT and histological findings","volume":"57","author":"Cleverley","year":"2002","journal-title":"Clin Radiol"},{"key":"10.1097\/JTO.0b013e318060d329_bib25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-03-0564","article-title":"United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets","volume":"10","author":"Cohen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e318060d329_bib26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1183\/09031936.03.00098503","article-title":"Acute lung injury as a possible adverse drug reaction related to gefitinib","volume":"22","author":"Ieki","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1097\/JTO.0b013e318060d329_bib27","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1517\/14740338.5.3.469","article-title":"Gefitinib: an adverse effects profile","volume":"5","author":"Cersosimo","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1097\/JTO.0b013e318060d329_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00002018-200528020-00002","article-title":"Interstitial lung disease in lung cancer: separating disease progression from treatment effects","volume":"28","author":"Danson","year":"2005","journal-title":"Drug Saf"},{"key":"10.1097\/JTO.0b013e318060d329_bib29","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.rmed.2005.07.015","article-title":"Interstitial lung disease associated with gefitinib","volume":"100","author":"Kataoka","year":"2006","journal-title":"Respir Med"},{"key":"10.1097\/JTO.0b013e318060d329_bib30","unstructured":"Yoneda K. Interstitial lung disease (ILD) with EGFR TKIs. Presented at the 7th International Lung Cancer Congress (Workshop), Maui, HI, 2006."}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530808X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641530808X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T04:52:45Z","timestamp":1546059165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641530808X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S155608641530808X"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e318060d329","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}